<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075604</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-7A8</org_study_id>
    <nct_id>NCT04075604</nct_id>
  </id_info>
  <brief_title>A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer</brief_title>
  <acronym>CheckMate 7A8</acronym>
  <official_title>Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer &gt;= 2 cm With Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized multi-arm study evaluating the safety and efficacy of palbociclib and&#xD;
      anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Adverse change in the risk/benefit&#xD;
  </why_stopped>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Actual">July 27, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Residual Cancer Burden RCB (0-1) rate by central assessment</measure>
    <time_frame>up to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>up to 34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>up to 34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs leading to Discontinuation</measure>
    <time_frame>up to 34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-related AEs</measure>
    <time_frame>up to 34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of laboratory abnormalities</measure>
    <time_frame>up to 34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (pCR) by local assessment</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Conserving Surgery (BCS) rate</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Palbociclib+ANZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)</arm_group_label>
    <arm_group_label>Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)</arm_group_label>
    <arm_group_label>Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ</arm_group_label>
    <arm_group_label>Arm C: Palbociclib+ANZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)</arm_group_label>
    <arm_group_label>Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ</arm_group_label>
    <arm_group_label>Arm C: Palbociclib+ANZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have untreated, unilateral, histologically confirmed ER+, HER2-&#xD;
             invasive breast cancer with primary tumor ≥2 cm in largest diameter (cT1-3) in one&#xD;
             dimension by clinical or radiographic exam, for whom neoadjuvant endocrine monotherapy&#xD;
             deemed to be a suitable therapy.&#xD;
&#xD;
          -  Participants must be deemed eligible for surgery and must agree to undergo surgery&#xD;
             after completion of neoadjuvant therapy and agree to provide tumor tissue at baseline,&#xD;
             on-treatment, and at surgery.&#xD;
&#xD;
          -  Women must have documented proof that they are not of childbearing potential.&#xD;
&#xD;
          -  Participants must have a performance status (PS) ≤ 1 on the Eastern Cooperative&#xD;
             Oncology Group (ECOG) scale&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who may have had any treatment, including radiotherapy, chemotherapy,&#xD;
             and/or targeted therapy administered for the currently diagnosed breast cancer prior&#xD;
             to enrollment or for whom upfront chemotherapy is clinically judged appropriate as&#xD;
             optimal neoadjuvant treatment.&#xD;
&#xD;
          -  Participants who have a history of or active, known or suspected autoimmune disease,&#xD;
             or other syndrome that requires systemic steroids above physiological replacement dose&#xD;
             or autoimmune agents for the past 2 years.&#xD;
&#xD;
          -  Prior treatment with either ET or CDK4/6 inhibitors for Breast Cancer (BC) within 5&#xD;
             years or an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways,&#xD;
             or history of allergy, or hypersensitivity to study drug components&#xD;
&#xD;
          -  Prior malignancy active within the previous 3 years or participants with serious or&#xD;
             uncontrolled medical disorders.&#xD;
&#xD;
          -  Personal history of any of the following conditions: syncope of either unexplained or&#xD;
             cardiovascular etiology, ventricular arrhythmia (including but not limited to&#xD;
             ventricular tachycardia and ventricular fibrillation), long or short QT syndrome,&#xD;
             Brugada syndrome, or known history of corrected QT prolongation, Torsade de Pointes,&#xD;
             or sudden cardiac arrest.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Blood Ctr</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital,Inc.- Central Research Department</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Center At Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates Of Fredricksburg, Inc</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Cancer Institute</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Central Districts Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Cancer Research Centre - WA</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Cancerologie du Grand Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>TOULOUSE Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation</name>
      <address>
        <city>Ponce</city>
        <zip>00717-2348</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion De Investigacion</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. Vall dHebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univer 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen De La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario De Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>ER+</keyword>
  <keyword>HER2-</keyword>
  <keyword>Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

